Flindokalner is primarily used in the development of central nervous system (CNS) therapies, particularly for its modulatory effects on ion channels involved in neuronal excitability. It has shown promise in preclinical studies as a potential treatment for certain types of epilepsy and neuropathic pain due to its ability to stabilize hyperexcitable neural membranes. Its mechanism supports targeted intervention in conditions involving abnormal electrical activity in the brain and peripheral nerves. Research is ongoing to evaluate its efficacy and safety in clinical settings, with a focus on optimizing dosing for therapeutic use without significant sedative side effects.